seed
Stage
2018
Founded
1
Investors
About
Develops programmable oligonucleotide therapeutics that autonomously silence disease-causing RNAs in human or pathogen cells, targeting genetically driven diseases, chronic conditions, and multidrug-resistant infections.
Explore 1E Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.